Form 4: Quest Diagnostics Executive Sam Samad Reports Stock and Option Transactions

Executive Vice President & CFO of Quest Diagnostics, Sam Samad, reports acquisition of restricted stock units and stock options.

Summary

• Sam Samad, Executive Vice President & CFO of Quest Diagnostics, filed a Form 4.
• On February 12, 2025, Samad acquired 4,538 shares of common stock and 17,403 non-qualified stock options.
• The common stock was acquired at a price of $0.
• The exercise price of the stock options is $165.3.
• The options vest in three equal annual installments beginning on the first annual anniversary of the grant date and expire on 02/12/2035.
• Following the reported transactions, Samad beneficially owns 22,077 shares of common stock and 17,403 derivative securities.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard regulatory filing detailing stock and option transactions by an executive. The transactions themselves don't inherently indicate positive or negative sentiment.

Positives

• The acquisition of stock and options by a high-ranking executive could be interpreted as a positive sign of confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The reported transactions may influence investor sentiment regarding Quest Diagnostics.

Key Dates